ImCheck Therapeutics vs Synthace
ImCheck Therapeutics vs Synthace, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: ImCheck Therapeutics is on 60/100 and Synthace on 62/100.
Where each one leads
ImCheck Therapeutics
- headcount: 47 against 37
- funding raised: $164M against $60.6M
Synthace
- agent readiness: 43/100 against 34/100
- domain rating: 54/100 against 37/100
At a glance
| Measure | ImCheck Therapeutics | Synthace |
|---|---|---|
| What it is | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. | Synthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing. |
| Category | Biotech, MedTech, HealthTech, Drug Discovery | Biotech, MedTech, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Biotech | Platform |
| Founded | 2015 | 2011 |
| Headquarters | Marseille, France | London, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | ImCheck Therapeutics | Synthace |
|---|---|---|
| Employees | 47 | 37 |
| Total funding | $164M | $60.6M |
| Latest round | Not published | Series C |
| LinkedIn followers | 11,647 | 14,388 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | ImCheck Therapeutics | Synthace |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 62/100 |
| Traction | 57/100 | 55/100 |
| Team | 70/100 | 70/100 |
| Community | 15/100 | Not published |
| Search visibility | 22/100 | 35/100 |
| Quality | 68/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (34/100) | D (43/100) |
| Domain ratingLink authority, 0-100 | 37/100 | 54/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | ImCheck Therapeutics | Synthace |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Not detected |
| Analytics | Google Analytics 4 | Google Tag Manager, Microsoft Clarity, Hotjar |
| Support stack | Not detected | HubSpot |
ImCheck Therapeutics vs Synthace: common questions
Which is better, ImCheck Therapeutics or Synthace?
On our 0-100 score Synthace rates higher (62/100 against 60/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do ImCheck Therapeutics and Synthace compare on the numbers?
ImCheck Therapeutics leads on headcount (47 against 37), funding raised ($164M against $60.6M). Synthace leads on agent readiness (43/100 against 34/100), domain rating (54/100 against 37/100).
Read the full ImCheck Therapeutics review and pricing or the Synthace review and pricing. You can also browse other ImCheck Therapeutics alternatives we track.